¿ Millennium Pharmaceuticals Inc., of Cambridge, appointed Kevin Starr chief financial officer; Sandra DiCesare vice president, information systems; Vincent Miles vice president, business and technology management; and Kazumi Shiosaki vice president, drug discovery.

¿ Nabi, of Boco Raton, Fla., appointed Bruce Farley senior vice president, manufacturing operations.

¿ Xenogenics Corp., of San Diego, a subsidiary of Exten Industries Inc., also of San Diego, named to its scientific board Alessandra Colantoni, research associate with the Department of Medicine in the Liver Transplant Service of the Division of Gastroenterology at Loyola University in Chicago.

¿ CuraGen Corp., of New Haven, Conn., appointed Lloyd Smith to its scientific advisory board. Smith, a Romnes Faculty Fellow and professor of chemistry at the University of Wisconsin-Madison, is credited with developing the first fluorescent-based automated DNA sequencing instrument.

¿ EnSolve Biosystems Inc., of Research Triangle Park, N.C., named Tom Laundon vice president of business development.

¿ Gene Logic Inc., of Gaithersburg, Md., named Mark Gessler president and chief operating officer.

¿ Genovo Inc., of Sharon Hill, Pa., named Gary Kurtzman chief operating officer and chairman of the research and development committee.

¿ Hollis-Eden Pharmaceuticals Inc., of San Diego, appointed Christopher Reading vice president of scientific development.

¿ Inspire Pharmaceuticals Inc., of Durham, N.C., promoted Gregory Mossinghoff to vice president, corporate development.

¿ IntraBiotics Pharmaceuticals Inc., of Mountain View, Calif., appointed Peter Garcia chief financial officer.

¿ Ixsys Inc., of San Diego, named William Huse chief executive officer, and Janine Taylor president and chief operating officer.

¿ Kosan Biosciences, of Burlingame, Calif., named Leonard Katz executive director, biological sciences and project management.

¿ Lexicon Genetics Inc., of The Woodlands, Texas, appointed Jeffrey Wade senior vice president and chief financial officer; Randall Riggs vice president of business development; and Michael Nehls vice president of genomics.

¿ Maxim Pharmaceuticals, of San Diego, appointed to its board of directors Theodor Heinrich, formerly with Hambrecht & Quist. Ram Rastogi was named vice president, clinical affairs.

¿ Medicis Pharmaceutical Corp., of Phoenix, named to its board of directors Spencer Davidson, president and CEO of General American Investors Co. Inc.

No Comments